{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:53:02Z","timestamp":1791942782028,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier","isbn-type":[{"value":"9780128211083","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.pbr.2020.05.013","type":"book-chapter","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T08:46:29Z","timestamp":1593506789000},"page":"171-206","source":"Crossref","is-referenced-by-count":10,"title":["OnabotulinumtoxinA injection in the treatment of chronic migraine"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2020.05.013_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0015","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ene.14102","article-title":"Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies","volume":"27","author":"Ailani","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1526-4610.2006.00624.x","article-title":"Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study","volume":"47","author":"Aurora","year":"2007","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0030","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11916-009-0048-3","article-title":"Overuse of acute migraine medications and migraine chronification","volume":"13","author":"Bigal","year":"2009","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1524-4725.1998.tb04098.x","article-title":"Treatment of hyperfunctional lines of the face with botulinum toxin A","volume":"24","author":"Binder","year":"1998","journal-title":"Dermatol. Surg."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0055","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0060","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","article-title":"Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety","volume":"90","author":"Blumenfeld","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","article-title":"The action of botulinum toxin on the neuro-muscular junction","volume":"109","author":"Burgen","year":"1949","journal-title":"J. Physiol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/jb.4.5.541-553.1919","article-title":"The occurrence of Bacillus botulinus in nature","volume":"4","author":"Burke","year":"1919","journal-title":"J. Bacteriol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0333102417737779","article-title":"Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial","volume":"38","author":"Carlsen","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","article-title":"Treatment of glabellar frown lines with C. botulinum-A exotoxin","volume":"18","author":"Carruthers","year":"1992","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","article-title":"CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","volume":"54","author":"Cernuda-Morollon","year":"2014","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Morollon","year":"2015","journal-title":"Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0333102415593088","article-title":"Treatment of medication-overuse headache: a systematic review","volume":"36","author":"Chiang","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0115","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3349\/ymj.2013.54.6.1542","article-title":"A proposal to prevent the \u201cMephisto sign\u201d side effect of botulinum toxin type A injection in chronic migraine","volume":"54","author":"Cho","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00006534-198908000-00027","article-title":"Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis","volume":"84","author":"Clark","year":"1989","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/head.13691","article-title":"Rapid onset of effect of Galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies","volume":"60","author":"Detke","year":"2020","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0130","first-page":"735","article-title":"Placebo effects in treating migraine and other headaches","volume":"11","author":"Diener","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","article-title":"Medication-overuse headache: a worldwide problem","volume":"3","author":"Diener","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0140","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0145","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","article-title":"Medication-overuse headache: risk factors, pathophysiology and management","volume":"12","author":"Diener","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","article-title":"Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study","volume":"45","author":"Dodick","year":"2005","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0165","doi-asserted-by":"crossref","first-page":"P197","DOI":"10.1186\/1129-2377-14-S1-P197","article-title":"OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT","volume":"14","author":"Dodick","year":"2013","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0170","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/0333102418825382","article-title":"Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0175","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Dominguez","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.145.3633.719","article-title":"Atrophy of skeletal muscle in Chick embryos treated with botulinum toxin","volume":"145","author":"Drachman","year":"1964","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.pbr.2020.05.013_bb0185","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1093\/brain\/awz366","article-title":"OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine","volume":"143","author":"Dressler","year":"2020","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0190","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0195","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786\u20131862) and the \u201csausage poison\u201d","volume":"53","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1526-4610.2005.05067.x","article-title":"Duration of migraine is a predictor for response to botulinum toxin type A","volume":"45","author":"Eross","year":"2005","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0205","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2147\/NDT.S33769","article-title":"Preventive treatment in migraine and the new US guidelines","volume":"9","author":"Estemalik","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0215","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1526-4610.2012.02288.x","article-title":"Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B","volume":"53","author":"Grogan","year":"2013","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/bs.pbr.2020.05.013_bb0220","first-page":"9","article-title":"The international classification of headache disorders: 2nd edition","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0225","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0230","author":"ICER"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0235","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","article-title":"Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A","volume":"125","author":"Jakubowski","year":"2006","journal-title":"Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0245","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/head.13713","article-title":"Wearing off effect of OnabotulinumtoxinA near the end of treatment cycle for chronic migraine: a 4-year clinical experience","volume":"60","author":"Khan","year":"2020","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1126\/science.103.2681.613","article-title":"The purification and crystallization of Clostridium botulinum type A toxin","volume":"103","author":"Lamanna","year":"1946","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0255","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","article-title":"Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study","volume":"363","author":"Lee","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","article-title":"Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal","volume":"19","author":"Lee","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0265","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.59.7.1011","article-title":"Features of medication overuse headache following overuse of different acute headache drugs","volume":"59","author":"Limmroth","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcma.2013.09.006","article-title":"Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study","volume":"77","author":"Lin","year":"2014","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0275","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/head.13115","article-title":"Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention Study","volume":"57","author":"Lipton","year":"2017","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0280","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/head.12657","article-title":"Effect of OnabotulinumtoxinA injection on depression in chronic migraine","volume":"55","author":"Maasumi","year":"2015","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0285","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/head.13638","article-title":"OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine","volume":"59","author":"Masters-Israilov","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0290","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0333102417724150","article-title":"Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe","volume":"37","author":"Matharu","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0295","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0300","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","article-title":"Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial","volume":"45","author":"Mathew","year":"2005","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0305","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","article-title":"Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache","volume":"48","author":"Mathew","year":"2008","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0310","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0315","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","article-title":"Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Naumann","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience","volume":"17","author":"Negro","year":"2015","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0325","series-title":"Botulinum toxin type A for the prevention of headaches in adults with chronic migraine","author":"Nice Technology Appraisal Guidance 260","year":"2012"},{"issue":"183\u2013265","key":"10.1016\/bs.pbr.2020.05.013_bb0330","first-page":"320","article-title":"Biology and genomic analysis of Clostridium botulinum","volume":"55","author":"Peck","year":"2009","journal-title":"Adv. Microb. Physiol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0335","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/brain\/awz052","article-title":"Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial","volume":"142","author":"Pijpers","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.pbr.2020.05.013_bb0340","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz368","article-title":"Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine","volume":"143","author":"Pijpers","year":"2020","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0345","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/pm\/pny282","article-title":"Wearing off response to OnabotulinumtoxinA in chronic migraine: analysis in a series of 193 patients","volume":"20","author":"Quintas","year":"2019","journal-title":"Pain Med."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0350","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1468-2982.2007.01315.x","article-title":"A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches","volume":"27","author":"Relja","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0355","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0360","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/0333102419847957","article-title":"Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure","volume":"39","author":"Ruff","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0365","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/head.12883","article-title":"The \u201cRam's horns sign\u201d: a case report of an unusual side effect of OnabotulinumtoxinA in a chronic migraine patient","volume":"56","author":"Russo","year":"2016","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0370","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0375","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0380","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles","volume":"12","author":"Scott","year":"1973","journal-title":"Invest. Ophthalmol."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0385","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","article-title":"Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study","volume":"26","author":"Silberstein","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0390","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0395","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","article-title":"Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0400","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0405","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/head.13446","article-title":"The effect of beginning treatment with Fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment","volume":"59","author":"Silberstein","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0415","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development Subcommittee of the American Academy of neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0420","author":"Taiwan National Health Insurance Bureau"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0425","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/infdis\/43.2.152","article-title":"Studies on botulinus toxin: 3. Acid precipitation of botulinus toxin","volume":"43","author":"Tessmer Snipe","year":"1928","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0430","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/clinids\/1.4.701","volume":"1","author":"Van Ermengem","year":"1979","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0435","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.12488","article-title":"Development of onabotulinumtoxinA for chronic migraine","volume":"1329","author":"Whitcup","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.pbr.2020.05.013_bb0440","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/head.13654","article-title":"Early onset of efficacy with Fremanezumab for the preventive treatment of chronic migraine","volume":"59","author":"Winner","year":"2019","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0445","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/head.13754","article-title":"A randomized trial to evaluate OnabotulinumtoxinA for prevention of headaches in adolescents with chronic migraine","volume":"60","author":"Winner","year":"2020","journal-title":"Headache"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s10194-018-0953-0","article-title":"Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL study","volume":"20","author":"Young","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/bs.pbr.2020.05.013_bb0455","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s10194-018-0952-1","article-title":"Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study","volume":"20","author":"Young","year":"2019","journal-title":"J. Headache Pain"}],"container-title":["Progress in Brain Research","Update on Emerging Treatments for Migraine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612320300558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:01:36Z","timestamp":1758751296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612320300558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211083"],"references-count":90,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2020.05.013","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}